[CANCER RESEARCH 61, 2665–2669, March 15, 2001]
t(11;14)(q23;q24) Generates an MLL-Human Gephyrin Fusion Gene along with a de
facto Truncated MLL in Acute Monoblastic Leukemia1
Naruo Kuwada, Fumihiko Kimura, Takuya Matsumura, Takuya Yamashita, Yukitsugu Nakamura, Naoki Wakimoto,
Takashi Ikeda, Ken Sato, and Kazuo Motoyoshi2
Third Department of Internal Medicine, National Defense Medical College, Saitama 359-8513, Japan
ABSTRACT
More than 20 different partner genes with MLL have been cloned from
leukemia cells with translocations involving chromosome 11 band q23
(11q23). All reported partner genes fused in-frame to MLL and the fusion
cDNA encode chimeric MLL proteins with a significant portion derived
from the partner genes. We analyzed one patient with de novo acute
monoblastic leukemia with t(11;14)(q23;q24) and identified that a human
homologue of gephyrin (human gephyrin) fused with MLL. Gephyrin is a
rat glycine receptor-associated protein, which forms submembranous
complexes and anchor glycine or ␥-aminobutyric acidA receptors to microtubules. Alternative splicing of human gephyrin gene created two
different forms of fusion cDNA. In one form, human gephyrin gene fused
in-frame to MLL exon 9, and the chimeric product had COOH terminus
of human gephyrin protein, including the tubulin binding site. In the other,
the reading frame terminated shortly after the fusion point. As a result,
only seven amino acids with no known function were attached to the NH2
terminus of MLL protein. The functional significance of this de facto
truncated MLL gene product is not clear.
INTRODUCTION
Recurring chromosomal aberrations play a crucial role in the tumorigenesis of a variety of human neoplasms, including hematological malignancies. Chromosomal translocations involving chromosome 11q23 have been observed in both acute myeloid and
lymphoblastic leukemias as well as in therapy-related leukemias (1–
6). Molecular cloning of translocation breakpoints revealed that a
gene called MLL (also called ALL-1, HRX, or HTRX) is rearranged
and has its breakpoints clustered within an 8.3-kb region (7). This
gene encodes a protein with a predicted molecular mass of 431 kDa
(8, 9). The wild-type MLL protein has three AT-hook DNA binding
domains, transcriptional activation and repression domains, multiple
zinc finger domains known as plant homeodomain fingers, and a
region homologous to mammalian DNA methyltransferases (10, 11).
The SET [Su-(var)3–9, enhancer of zeste, and trithorax] domain in the
COOH terminus of MLL, along with the plant homeodomain fingers,
are conserved with the Drosophila trx3 gene. trx is a positive regulator
of homeobox gene expression and is involved in segment determination in Drosophila. MLL is thought to be the mammalian homologue
of the Drosophila homeobox regulating gene, trx, because mice with
a mutant Mll gene (the mouse orthologue of MLL) develop homeotic
transformations (12).
Chromosome translocations involving MLL create in-frame fusion
products of the NH2 terminus of MLL with different partner proteins
(13–15). More than 20 partner genes have been cloned to date (10,
Received 7/6/00; accepted 1/16/01.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1
Supported by a grant from the Research Foundation For Community Medicine.
2
To whom requests for reprints should be addressed, at National Defense Medical
College, Third Department of Internal Medicine, 3-2 Namiki, Tokorozawa, Saitama
359-8513, Japan. Phone: 81-42-995-1617; Fax: 81-42-996-5202; E-mail: motoyosi@me.
ndmc.ac.jp.
3
The abbreviations used are: trx, trithorax; RACE, rapid amplification of cDNA ends;
RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EST, expression sequence tag.
16 –19). Moreover, partial tandem duplications of MLL appear to be
frequently encountered in adult acute myeloid leukemia, particularly
in association with trisomy 11 (20). All partner genes are fused
in-frame to MLL, resulting in novel fusion proteins, rather than simply
a truncation of MLL. As to oncogenesis derived from MLL translocations, a two-hit model has been suggested (12): (a) MLL fusion
products cause haplo-insufficiency of the MLL COOH-terminal portion; and (b) partner genes could confer gain-of-function activity.
Several groups have tried to elucidate the effects of these two events
using various forms of MLL fusion or truncated MLL constructs
(21–27).
In the present study, we have identified human gephyrin as a novel
fusion partner of MLL from a patient who presented with a de novo
acute monoblastic leukemia with t(11;14)(q23;q24). This rare chromosomal translocation has been reported in a limited number of
leukemia patients (28, 29). gephyrin was originally recognized as a rat
protein that copurified with glycine receptors in inhibitory neurons of
the central nervous system (30). It is a cytoplasmic protein that is
known to anchor glycine or ␥-aminobutyric acidA receptors to subsynaptic microtubules (31, 32). We were able to identify two MLLhuman gephyrin fusion products, presumably attributable to the alternative splicing of human gephyrin. In one product, MLL was fused
in-frame to the human gephyrin gene, and the resultant fusion protein
contained the NH2 terminus of MLL and the COOH terminus of the
human gephyrin protein. However, in the second product, only seven
amino acids were attached to the NH2-terminal portion of the MLL
protein, generating the shortest partner amino acid sequence among
those reported. This fusion product may be considered as a de facto
truncated form of MLL. On the basis of these findings, we discuss here
possible mechanisms by which these MLL-human gephyrin fusion
products contribute to leukemogenesis.
PATIENT AND METHODS
Patient. A 67-year-old female was diagnosed with acute monoblastic leukemia with hyperleukocytosis. Chromosomal analysis showed t(11;14)(q23;
q24). She received chemotherapy consisting of idarubicin and cytarabine with
leukapheresis, but on day 2, she died of renal and respiratory failure. Autopsy
revealed marked systemic infiltration of leukemic cells.
Southern Blot Analysis. High molecular weight DNA was extracted from
bone marrow cells of the donor using the GENOMIX kit (Talent s.r.l., Trieste,
Italy). After digestion with a restriction enzyme, BamHI, the DNA was
subjected to electrophoresis on a 0.7% agarose gel, transferred to a charged
nylon filter, and hybridized with a cDNA probe. A 0.9-kb BamHI fragment
derived from MLL cDNA was labeled by the random primer method (High
Prime; F. Hoffmann-La Roche Ltd., Basel, Switzerland) and used as a probe.
Panhandle PCR. High molecular weight DNA was extracted from peripheral blood cells using Qiagen Genomic-tip 100/G and Genomic DNA Buffer
set (Qiagen, Hilden, Germany). Five ␮g of genomic DNA were analyzed by
panhandle PCR as reported previously (33).
3ⴕ RACE. Total cellular RNA was extracted from peripheral blood cells of
the patient using Isogen (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
The RNA was subjected to the rapid amplification of cDNA ends technique
using a 3⬘ RACE kit (Life Technologies, Inc., Grand Island, NY). The
gene-specific primers used were MLL primer 1 (5⬘-TCC TCC ACG AAA GCC
2665
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.
MLL-HUMAN GEPHYRIN FUSION IN t(11;14)(q23;q24)
CGT CGA G-3⬘) from MLL exon 8 and reverse primer (5⬘-AGC AAA CAG
AAA AAA GTG GCT CCC-3⬘) from MLL exon 9.
Genomic PCR and RT-PCR. Five hundred ng of genomic DNA were
amplified by PCR in a total volume of 25 ␮l with the Taq PCR core kit
(Qiagen). After 35 rounds of PCR (30 s at 94°C, 30 s at 56°C, and 2 min at
72°C), 5 ␮l of PCR product were electrophoresed on a 3% agarose gel. The
primers used for genomic PCR were forward primer (5⬘- TGA TTC CTG TCC
ATA GAA ATG CAA ATA AGT-3⬘), reverse control primer (5⬘-TGG TGA
CTT CTT CTT GGT AAA TGA TAC GGA-3⬘) from chromosome 14 sequence (accession no. AL049835.3), and reverse primer (described above). For
RT-PCR, total RNA (1 ␮g) was reverse transcribed to cDNA in a total volume
of 20 ␮l with random nonamers and 5 units of reverse transcriptase (RNA PCR
kit version 2; TaKaRa Shuzo Co., Ltd., Kyoto, Japan). The cDNA (0.5 ␮l) was
amplified by 35 rounds of PCR (30 s at 94°C, 30 s at 55°C, and 1 min at 72°C).
Oligonucleotides used were MLL primer 1 (described above) and GSP2 (5⬘TGC TGG GAA GGG GGG TAA ATT GT-3⬘), from human gephyrin exon
11, for MLL-human gephyrin fusion; gephyrin 552F (5⬘-AGA TGT CAC TCC
AGA GGC CAC A-3⬘), from human gephyrin exons 4 and 5, and MLL exon
11 (5⬘-GGC ACA GAG AAA GCA AAC CA-3⬘) for human gephyrin-MLL
fusion; GAPDH F1 (5⬘-ACA TCG CTC AGA CAC CAT GG-3⬘) and GAPDH
R1 (5⬘-GTA GTT GAG GTC AAT GAA GGG-3⬘) for GAPDH as a control.
A nested PCR reaction using a 0.5-␮l aliquot of the first reaction because
template DNA enhanced the yield. The primers used for nested PCR were
reverse primer (described above) and GSP3 (5⬘-TTG AGC AAG GAC TCG
CCC CAT T-3⬘), from human gephyrin exon 11, for MLL-human gephyrin
fusion; gephyrin exon 7 (5⬘-AAG ATT TGC CTT CCC CAC CT-3⬘), from
human gephyrin exon 7, and MLL exon 10 (5⬘-TGC CAT TGG AGA GAG
TGC TGA G-3⬘) for human gephyrin-MLL fusion. Conditions for nested PCR
were the same as in the initial RT-PCR, and the PCR products were electrophoresed as outlined above.
Nucleotide Sequencing. The PCR products were cloned into a TA cloning
vector (Invitrogen Corp., Carlsbad, CA). The nucleotide sequences of PCR
products were determined by the fluorescently labeled dideoxy terminators
(BigDye Terminator Cycle Sequencing FS Ready Reaction kit; Applied Biosystems, Tokyo, Japan) on a 377 Applied Biosystems automated sequencer. To
obtain entire sequences, some PCR products were truncated using a Deletion
Kit for Kilo-Sequencing (TaKaRa Shuzo Co., Ltd.).
RESULTS
Genomic DNA Cloning of the t(11;14). Southern blot analysis of
DNA from the leukemic cells digested with BamHI demonstrated two
rearranged bands by the use of an MLL probe (Fig. 1). To identify the
partner gene, we carried out panhandle PCR. A sequencing analysis of
the 4.2-kb PCR product revealed that the MLL gene was fused to an
unknown sequence in intron 9 (according to the exon-intron structure
Fig. 2. Panhandle PCR products from der(11) chromosome. The MLL gene was
truncated in intron 9, and the 3⬘ sequence was replaced by the chromosome 14 genome
sequence, AL049835.3. The breakpoint of the MLL gene is located between nucleotide
positions 748 and 749 (numbering according to the 11q23-breakpoint sequence with
accession no. HSU04737). In the chromosome 14 genomic sequence, the breakpoint is
found between positions 163453 and 163454 of AL049835.3.
reported by Nilson et al. (8). In a BLAST database search,4 this
unknown sequence matched the genomic sequence from chromosome
14 (Fig. 2). We verified the fusion by genomic PCR (data not shown).
Furthermore, the breakpoint was not found within Alu repetitive
sequences. We could not find the partner gene within this PCR
product because no EST clones matched the unknown sequence.
3ⴕ RACE Analysis. To explore the fusion partner gene at the
cDNA level, we performed 3⬘ RACE. The two clones obtained both
had partner sequences fused to MLL exon 9. One clone, having the
shorter partner sequence, was named clone A, and the second, having
the longer sequence, was named clone B. In a database search, these
partners showed high homology to a rat cDNA sequence (accession
no. X66366) for gephyrin, a glycine receptor-associated protein (Fig.
3A). Recently, a human cDNA sequence almost identical to rat gephyrin cDNA was reported (Ref. 34; KIAA1385, accession no.
AB037806). We herein refer to this gene as human gephyrin. However, clone B contains an insert that does not have any corresponding
sequence either in rat or human gephyrin cDNA. The insert sequence
was assumed to be an exon sequence in an alternatively spliced form
of human gephyrin, because it is found in the chromosome genome
sequence (Fig. 4) with splicing donor and acceptor sites (Fig. 3B) and
in a human EST (accession no. AA377065) from the small intestine
cDNA library.
Human Homologue of gephyrin. We performed public database
searches for information about human gephyrin. The cDNA clone
KIAA1385 is highly homologous to rat gephyrin cDNA as well as
clones A and B. This clone has 4193 bp with an open reading frame
of 2304 bp. However, the start codon has not as yet been identified.
By analogy to the rat gephyrin sequence, the start codon is assumed
to be located within nucleotides 1122–1124, and the open reading
frame may encode 736 amino acids. The predicted amino acid sequence of KIAA1385 and the rat gephyrin amino acid sequence show
⬎99% identity. These findings suggest that KIAA1385 is the human
homologue of rat gephyrin cDNA. The entire sequence of KIAA1385
has corresponding chromosome 14 genome sequences in the GenBank
database (Fig. 4). A homology search within other organisms revealed
that gephyrin has two domains (MogA and MoeA domains) that are
homologous to proteins of the molybdenum cofactor synthesis pathway. Sequence inspection identified a proline-rich motif between
Fig. 1. Southern blot of DNA was digested with BamHI and probed with the 0.9-kb
fragment of the MLL gene. Lane C, normal control; Lane Pt, leukemic cells from the
patient. Two rearranged bands (arrows) were detected in the patient sample.
4
Internet address: http://www.ncbi.nlm.nih.gov/BLAST.
2666
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.
MLL-HUMAN GEPHYRIN FUSION IN t(11;14)(q23;q24)
Fig. 3. 3⬘ RACE products. A, two clones containing the MLL gene and partner gene
sequences. The partner gene sequence shows high homology with rat gephyrin cDNA and
human gephyrin cDNA KIAA1385. Clone B contains an insert indicated by the hatched
box. This insert did not have a corresponding sequence either in rat or human gephyrin
cDNA. B, the insert sequence in clone B. The intron sequence predicted by the genome
sequence is shown in italics. The insert sequence has splicing donor and recipient sites on
either ends (boldface italics).
amino acids 219 and 233 and a tubulin binding site between amino
acids 320 and 331. Furthermore, human gephyrin appears to be
ubiquitously expressed, with high expression in brain, liver, and
kidney as identified in the HUGE database.5
Analysis of Fusion Products. We verified the MLL-human gephyrin fusion by RT-PCR and obtained products of predicted sizes only
within the patient sample (Fig. 5A). Analysis of the fusion point
revealed an in-frame fusion between MLL exon 9 and the human
gephyrin homologue in clone A (Fig. 5B). In clone B, the reading
frame terminated shortly downstream to the fusion point. These findings suggest that there should arise two chimeric proteins from MLL
and human gephyrin fusion. We named these proteins MLL-gephyrin
A and MLL-gephyrin B, respectively, according to the 3⬘ RACE
clones. The MLL-gephyrin A protein consists of AT-hooks, a methyltransferase, and transcription repressor domains of MLL, in addition
to the human gephyrin MoeA domain and the tubulin binding motif.
The MLL-gephyrin B protein contains the NH2 terminal portion of
MLL and seven amino acids from the partner gene.
eton. It is essential for the localization of inhibitory glycine or ␥-aminobutyric acidA receptors to presumptive postsynaptic sites (31, 32).
In this process, the gephyrin protein is thought to form clusters under
the plasma membrane. gephyrin contains two domains that are homologous to the Escherichia coli proteins in the molybdenum cofactor
synthesis pathway. Gene targeting studies demonstrate that gephyrin
is required both for synaptic clustering of glycine receptors in the
spinal cord and for molybdoenzyme activity in nonneural tissues.
Furthermore, gephyrin has been shown to interact with RAFT1
(FRAP) (Ref. 35). RAFT1 is an ATM-related protein that appears to
participate in mitogen-stimulated signaling, and RAFT1 mutants that
could not associate with gephyrin failed to signal to downstream
molecules. The COOH-terminal portion of gephyrin, including the
proline-rich motif and the tubulin binding site, was necessary for this
interaction, but the precise RAFT1 binding site has as yet to be
identified. The gephyrin-binding region of RAFT1 shares sequence
similarity with the intracellular loops of the ␤ subunit of the glycine
receptor. Several other proteins that associate with gephyrin have been
reported. Collybistin, a newly identified brain-specific GDP/GTP exchange factor, induces submembrane clustering of gephyrin (36).
Profilin, an actin monomer-binding protein that stimulates actin polymerization, binds to the proline-rich motif of gephyrin (37).
To date, ⬎20 different partner genes for MLL have been reported
(10, 16 –19). Many of the partners are nucleoproteins that show
homology to transcriptional factors or have known roles in transcriptional regulation. This has led to the hypothesis that MLL translocations create chimeric transcription factors. Recently, however, several
fusion partners that appear to be cytoplasmic proteins have been
reported. For example, AF6 is a putative ras effector and component
of tight junctions (38, 39) that has been shown to bind both ras and the
tight junction protein ZO-1. Moreover, AF6 is thought to mediate
the clustering of Eph receptors at postsynaptic specialization sites in
the adult rat brain (40, 41). Therefore, AF6 and gephyrin may act
similarly through interactions with receptor molecules. However, it is
unclear whether these properties actually contribute to leukemogenesis, because the MLL-AF6 fusion product was located in the nucleus
(42). Subcellular localization of the MLL-human gephyrin fusion
proteins and the function that the cytoplasmic family of fusion partners gives to MLL fusion products are of future interest.
The 3⬘ RACE analysis resulted in two forms of fusion products.
Different forms of fusion products have been observed in patients
with MLL-AF4, MLL-AF9, MLL-CBP, and MLL-ENL fusions (43–
DISCUSSION
Cloning of the t(11;14) breakpoint of a de novo acute monoblastic
leukemia has demonstrated that MLL fused to the human gephyrin
gene. The t(11;14)(q23;q24) is an extremely rare chromosomal abnormality with only two reports in the literature (28, 29). However,
MLL rearrangement was not examined in these cases. The breakpoint
of the MLL gene was within the breakpoint cluster region described
previously. Neither MLL nor the chromosome 14 genome sequence
has Alu sequences near the genomic fusion point; therefore, it is
unlikely that homologous recombination has caused this translocation.
The human gephyrin gene is highly homologous to the rat gephyrin
gene. The rat gephyrin gene encoding a Mr 93,000 protein was cloned
in 1992 (30). Gephyrin is known to be a receptor-associated protein
linking the ␤ subunit of glycine receptors to the subsynaptic cytoskel5
Internet address: http://www.kazusa.or.jp/huge.
Fig. 4. Structure of human gephyrin. Top, genome structure; each line represents a
genome contig. The breakpoint is shown by an arrow on AL049835.3. Middle, human
gephyrin was supposed to consist of 22 exons (boxes on dashed line). The box with (ⴱ)
between exons 7 and 8, the insert sequence of 3⬘ RACE clone B. Bottom, putative domain
structure of human gephyrin protein. a.a., amino acid(s).
2667
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.
MLL-HUMAN GEPHYRIN FUSION IN t(11;14)(q23;q24)
Fig. 5. Structure of the MLL-human gephyrin
fusion proteins. A, detection of the fusion transcripts by RT-PCR. Lane M, size marker; Lane P,
leukemic cells from the patient; Lane C, normal
control. Lanes 1 and 2 contain positive control
amplifications of GAPDH. Both the MLL-human
gephyrin and human gephyrin-MLL fusion transcripts were found in the patient sample (Lanes 3
and 5). B, the putative fusion proteins suggested by
3⬘ RACE clones were designated MLL-gephyrin A
and B, respectively. In MLL-gephyrin A, MLL exon
9 was fused in-frame to human gephyrin exon 8. In
MLL-gephyrin B, the reading frame terminates
briefly after the fusion point.
47). In a case with complex chromosomal abnormality, two partner
genes were found to make dual fusion products with MLL (48).
Moreover, a single aberration, cryptic t(11;17), resulted in two inframe MLL fusion cDNAs in a patient because of alternative splicing
of the MLL gene (17). In our case, the two fusion clones might have
been caused by an alternately spliced human gephyrin gene. The rat
gephyrin gene has seven different cDNA forms isolated from spinal
and brain cDNA libraries (30). The insert sequence in our clone B was
detected in the chromosome 14 genome sequence and in a human EST
clone. In addition, it has splice donor and acceptor sites on either end
of the genome sequence. These observations suggest that the insert
sequence represents an exon sequence in an alternatively spliced form
of human gephyrin.
The fusion product encoded by clone A has the NH2 terminus of
MLL and the COOH terminus of the human gephyrin homologue. The
tubulin binding site is retained, allowing the MLL- gephyrin A product
to interact with microtubules. RAFT1 and glycine receptors may also
bind to the fusion protein. Interactions with these and other proteins
may confer some function to the MLL NH2-terminal portion. Although the region required for cluster formation remains unknown,
oligomerization is another possible property of the fusion product. In
MLL-bacterial lacZ fusion knock-in mice, the artificial fusion gene
causes leukemia, as do the naturally occurring fusion genes (49). lacZ
has tetramer formation features and could contribute to leukemogenesis through oligomerization of the MLL-lacZ fusion protein.
In clone B, the reading frame terminates immediately after the
breakpoint. The partner gene provides only seven amino acids containing no known features to the NH2 terminus of the MLL protein.
This is the shortest fusion partner portion of those reported. In fact,
this fusion product may be equivalent to a truncated MLL protein.
MLL gene rearrangement may have two effects on tumorigenesis
(12). One is the removal of the MLL COOH-terminal sequence, which
may cause haplo-insufficiency of MLL and work on the wild-type
MLL as a dominant-negative form. The second is the positive contribution of gaining specific fusion partners. These hypotheses have
been examined by introducing various fusion genes and truncated
MLL. In myelomonocytic or monocytic cell lines, truncated MLL as
well as MLL-partner gene fusion products can affect cell growth,
differentiation, homeobox gene expression, or cell cycle (21–23).
However, the truncated MLL gene could not induce leukemia when it
was introduced into mouse embryonic stem cells or bone marrow cells
(24 –27). In knock-in mice, the Mll-AF9 fusion gene caused leukemia
after a myeloproliferative state (25). The late onset of overt tumors
suggests that additional genetic events are required for leukemogenesis.
In our case, further study is required to elucidate which of the MLL
fusion products may be responsible for leukemogenesis. However, the
clone B product is less likely to be sufficient for transformation. All
cloned 11q23 translocations have produced in-frame fusion genes
containing significant amounts of the partner sequences. This observation implies selection for a translatable or functional transcript in
the process of leukemogenesis (10). Furthermore, there may be ongoing MLL fusion events in healthy individuals. MLL-AF4 fusion
products and multiple MLL partial tandem duplication products have
been detected in healthy individuals by RT-PCR (50, 51). In the latter,
the estimated mean number of duplication positive cells in healthy
blood donors is 1 in ⱕ5000 cells. However, the MLL disruption may
have to survive three rounds of selection before causing leukemia: (a)
in-frame fusion with a significant portion of the partner gene is
needed; (b) this must occur in hematopoietic cells within a developmental window of vulnerability (10). It is at this point that cells with
MLL aberrations gain proliferative or survival advantage; and (c)
additional genetic hits liberate leukemic transformation. According to
this hypothesis, the short form of the MLL-human gephyrin fusion
may be an example of a nonfunctional MLL fusion product that we
were able to identify incidentally, by virtue of the leukemia caused by
the longer form of the MLL-human gephyrin fusion protein. Our
patient revealed a novel MLL-partner gene fusion along with a de
facto truncated MLL gene. Further studies on this abnormality will
contribute to understanding MLL-mediated leukemogenesis.
REFERENCES
1. Cimino, G., Moir, D. T., Canaani, O., Williams, K., Crist, W. M., Katzav, S.,
Cannizzaro, L., Lange, B., Nowell, P. C., Croce, C. M., et al. Cloning of ALL-1, the
locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;
19)(q23;p13) chromosome translocations. Cancer Res., 51: 6712– 6714, 1991.
2. Djabali, M., Selleri, L., Parry, P., Bower, M., Young, B. D., and Evans, G. A. A
trithorax-like gene is interrupted by chromosome 11q23 translocations in acute
leukaemias. Nat. Genet., 2: 113–118, 1992.
3. Tkachuk, D. C., Kohler, S., and Cleary, M. L. Involvement of a homolog of
Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell,
71: 691–700, 1992.
4. Ziemin-van der Poel, S., McCabe, N. R., Gill, H. J., Espinosa, R., III, Patel, Y.,
Harden, A., Rubinelli, P., Smith, S. D., LeBeau, M. M., Rowley, J. D., et al.
Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations
associated with human leukemias. Proc. Natl. Acad. Sci. USA, 88: 10735–10739,
1991.
5. Pui, C. H., Relling, M. V., Rivera, G. K., Hancock, M. L., Raimondi, S. C., Heslop,
H. E., Santana, V. M., Ribeiro, R. C., Sandlund, J. T., Mahmoud, H. H., et al.
Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia
(Baltimore), 9: 1990 –1996, 1995.
6. Smith, M. A., McCaffrey, R. P., and Karp, J. E. The secondary leukemias: challenges
and research directions. J. Natl. Cancer Inst., 88: 407– 418, 1996.
7. Gu, Y., Alder, H., Nakamura, T., Schichman, S. A., Prasad, R., Canaani, O., Saito, H.,
Croce, C. M., and Canaani, E. Sequence analysis of the breakpoint cluster region in
the ALL-1 gene involved in acute leukemia. Cancer Res., 54: 2326 –2330, 1994.
2668
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.
MLL-HUMAN GEPHYRIN FUSION IN t(11;14)(q23;q24)
8. Nilson, I., Lochner, K., Siegler, G., Greil, J., Beck, J. D., Fey, G. H., and Marschalek,
R. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations
to chromosomal region 11q23 and acute leukaemias. Br. J. Haematol., 93: 966 –972,
1996.
9. Rasio, D., Schichman, S. A., Negrini, M., Canaani, E., and Croce, C. M. Complete
exon structure of the ALL1 gene. Cancer Res., 56: 1766 –1769, 1996.
10. Dimartino, J. F., and Cleary, M. L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br. J. Haematol., 106: 614 – 626,
1999.
11. Prasad, R., Yano, T., Sorio, C., Nakamura, T., Rallapalli, R., Gu, Y., Leshkowitz, D.,
Croce, C. M., and Canaani, E. Domains with transcriptional regulatory activity within
the ALL1 and AF4 proteins involved in acute leukemia. Proc. Natl. Acad. Sci. USA,
92: 12160 –12164, 1995.
12. Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A., and Korsmeyer, S. J. Altered Hox
expression and segmental identity in Mll-mutant mice. Nature (Lond.), 378: 505–508,
1995.
13. Thirman, M. J., Gill, H. J., Burnett, R. C., Mbangkollo, D., McCabe, N. R.,
Kobayashi, H., Ziemin-van der Poel, S., Kaneko, Y., Morgan, R., Sandberg, A. A., et
al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid
leukemias with 11q23 chromosomal translocations. N. Engl. J. Med., 329: 909 –914,
1993.
14. Bernard, O. A., and Berger, R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer, 13: 75– 85, 1995.
15. Waring, P. M., and Cleary, M. L. Disruption of a homolog of trithorax by 11q23
translocations: leukemogenic and transcriptional implications. Curr. Top. Microbiol.
Immunol., 220: 1–23, 1997.
16. Taki, T., Kano, H., Taniwaki, M., Sako, M., Yanagisawa, M., and Hayashi, Y.
AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute
lymphoblastic leukemia with ins(5;11)(q31;q13q23). Proc. Natl. Acad. Sci. USA, 96:
14535–14540, 1999.
17. Megonigal, M. D., Cheung, N. K., Rappaport, E. F., Nowell, P. C., Wilson, R. B.,
Jones, D. H., Addya, K., Leonard, D. G., Kushner, B. H., Williams, T. M., Lange,
B. J., and Felix, C. A. Detection of leukemia-associated MLL-GAS7 translocation
early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl. Acad.
Sci. USA, 97: 2814 –2819, 2000.
18. Sano, K., Hayakawa, A., Piao, J. H., Kosaka, Y., and Nakamura, H. Novel SH3
protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein
in a therapy-related leukemia with t(3;11)(p21;q23). Blood, 95: 1066 –1068, 2000.
19. Kourlas, P. J., Strout, M. P., Becknell, B., Veronese, M. L., Croce, C. M., Theil, K. S.,
Krahe, R., Ruutu, T., Knuutila, S., Bloomfield, C. D., and Caligiuri, M. A. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for
its fusion with MLL in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA, 97:
2145–2150, 2000.
20. Schichman, S. A., Caligiuri, M. A., Gu, Y., Strout, M. P., Canaani, E., Bloomfield,
C. D., and Croce, C. M. ALL-1 partial duplication in acute leukemia. Proc. Natl. Acad.
Sci. USA, 91: 6236 – 6239, 1994.
21. Joh, T., Kagami, Y., Yamamoto, K., Segawa, T., Takizawa, J., Takahashi, T., Ueda,
R., and Seto, M. Identification of MLL and chimeric MLL gene products involved in
11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation.
Oncogene, 13: 1945–1953, 1996.
22. Joh, T., Hosokawa, Y., Suzuki, R., Takahashi, T., and Seto, M. Establishment of an
inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox
a7, Hox b7, and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells. Oncogene, 18:
1125–1130, 1999.
23. Caslini, C., Shilatifard, A., Yang, L., and Hess, J. L. The amino terminus of the mixed
lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc. Natl. Acad. Sci. USA, 97: 2797–2802, 2000.
24. Corral, J., Lavenir, I., Impey, H., Warren, A. J., Forster, A., Larson, T. A., Bell, S.,
McKenzie, A. N., King, G., and Rabbitts, T. H. An Mll-AF9 fusion gene made by
homologous recombination causes acute leukemia in chimeric mice: a method to
create fusion oncogenes. Cell, 85: 853– 861, 1996.
25. Dobson, C. L., Warren, A. J., Pannell, R., Forster, A., Lavenir, I., Corral, J., Smith,
A. J., and Rabbitts, T. H. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J., 18: 3564 –3574, 1999.
26. Lavau, C., Szilvassy, S. J., Slany, R., and Cleary, M. L. Immortalization and leukemic
transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.
EMBO J. 16: 4226 – 4237, 1997.
27. Slany, R. K., Lavau, C., and Cleary, M. L. The oncogenic capacity of HRX-ENL
requires the transcriptional transactivation activity of ENL and the DNA binding
motifs of HRX. Mol. Cell. Biol., 18: 122–129, 1998.
28. Sulak, L. E., Clare, C. N., Morale, B. A., Hansen, K. L., and Montiel, M. M.
Biphenotypic acute leukemia in adults. Am. J. Clin. Pathol., 94: 54 –58, 1990.
29. Palka, G., Calabrese, G., Stuppia, L., Guanciali Franchi, P., Antonucci, A., Spadano,
A., Di Lorenzo, R., and Torlontano, G. Leukemic evolution in three patients with
myelodysplastic syndrome and unusual chromosome changes. Cancer Genet. Cytogenet., 61: 162–164, 1992.
30. Prior, P., Schmitt, B., Grenningloh, G., Pribilla, I., Multhaup, G., Beyreuther, K.,
Maulet, Y., Werner, P., Langosch, D., Kirsch, J., et al. Primary structure and
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
alternative splice variants of gephyrin, a putative glycine receptor-tubulin linker
protein. Neuron, 8: 1161–1170, 1992.
Kirsch, J., Wolters, I., Triller, A., and Betz, H. Gephyrin antisense oligonucleotides
prevent glycine receptor clustering in spinal neurons. Nature (Lond.), 366: 745–748,
1993.
Essrich, C., Lorez, M., Benson, J. A., Fritschy, J. M., and Luscher, B. Postsynaptic
clustering of major GABAA receptor subtypes requires the ␥2 subunit and gephyrin.
Nat. Neurosci., 1: 563–571, 1998.
Felix, C. A., Kim, C. S., Megonigal, M. D., Slater, D. J., Jones, D. H., Spinner, N. B.,
Stump, T., Hosler, M. R., Nowell, P. C., Lange, B. J., and Rappaport, E. F. Panhandle
polymerase chain reaction amplifies MLL genomic translocation breakpoint involving
unknown partner gene. Blood, 90: 4679 – 4686, 1997.
Nagase, T., Kikuno, R., Ishikawa, K. I., Hirosawa, M., and Ohara, O. Prediction of the
coding sequences of unidentified human genes. DNA Res., 7: 65–73, 2000.
Sabatini, D. M., Barrow, R. K., Blackshaw, S., Burnett, P. E., Lai, M. M., Field,
M. E., Bahr, B. A., Kirsch, J., Betz, H., and Snyder, S. H. Interaction of RAFT1 with
gephyrin required for rapamycin-sensitive signaling. Science (Washington DC), 284:
1161–1164, 1999.
Kins, S., Betz, H., and Kirsch, J. Collybistin, a newly identified brain-specific GEF,
induces submembrane clustering of gephyrin. Nat. Neurosci., 3: 22–29, 2000.
Mammoto, A., Sasaki, T., Asakura, T., Hotta, I., Imamura, H., Takahashi, K.,
Matsuura, Y., Shirao, T., and Takai, Y. Interactions of drebrin and gephyrin with
profilin. Biochem. Biophys. Res. Commun., 243: 86 – 89, 1998.
Kuriyama, M., Harada, N., Kuroda, S., Yamamoto, T., Nakafuku, M., Iwamatsu, A.,
Yamamoto, D., Prasad, R., Croce, C., Canaani, E., and Kaibuchi, K. Identification of
AF-6 and canoe as putative targets for Ras. J. Biol. Chem., 271: 607– 610, 1996.
Yamamoto, T., Harada, N., Kano, K., Taya, S., Canaani, E., Matsuura, Y., Mizoguchi,
A., Ide, C., and Kaibuchi, K. The Ras target AF-6 interacts with ZO-1 and serves as
a peripheral component of tight junctions in epithelial cells. J. Cell Biol., 139:
785–795, 1997.
Hock, B., Bohme, B., Karn, T., Yamamoto, T., Kaibuchi, K., Holtrich, U., Holland,
S., Pawson, T., Rubsamen-Waigmann, H., and Strebhardt, K. PDZ-domain-mediated
interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding
protein AF6 depends on the kinase activity of the receptor. Proc. Natl. Acad. Sci.
USA, 95: 9779 –9784, 1998.
Buchert, M., Schneider, S., Meskenaite, V., Adams, M. T., Canaani, E., Baechi, T.,
Moelling, K., and Hovens, C. M. The junction-associated protein AF-6 interacts and
clusters with specific Eph receptor tyrosine kinases at specialized sites of cell-cell
contact in the brain. J. Cell Biol., 144: 361–371, 1999.
Joh, T., Yamamoto, K., Kagami, Y., Kakuda, H., Sato, T., Yamamoto, T., Takahashi,
T., Ueda, R., Kaibuchi, K., and Seto, M. Chimeric MLL products with a Ras binding
cytoplasmic protein AF6 involved in t(6;11)(q27;q23) leukemia localize in the
nucleus. Oncogene, 15: 1681–1687, 1997.
Nilson, I., Reichel, M., Ennas, M. G., Greim, R., Knorr, C., Siegler, G., Greil, J., Fey,
G. H., and Marschalek, R. Exon/intron structure of the human AF-4 gene, a member
of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural
alterations in acute leukaemia. Br. J. Haematol., 98: 157–169, 1997.
Reichel, M., Gillert, E., Nilson, I., Siegler, G., Greil, J., Fey, G. H., and Marschalek,
R. Fine structure of translocation breakpoints in leukemic blasts with chromosomal
translocation t(4;11): the DNA damage-repair model of translocation. Oncogene, 17:
3035–3044, 1998.
Sobulo, O. M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B.,
Housman, D., Doggett, N. A., Rowley, J. D., and Zeleznik-Le, N. J. MLL is fused to
CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a
t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. USA, 94: 8732– 8737, 1997.
Super, H. G., Strissel, P. L., Sobulo, O. M., Burian, D., Reshmi, S. C., Roe, B.,
Zeleznik-Le, N. J., Diaz, M. O., and Rowley, J. D. Identification of complex genomic
breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia. Genes
Chromosomes Cancer, 20: 185–195, 1997.
Yamamoto, K., Seto, M., Komatsu, H., Iida, S., Akao, Y., Kojima, S., Kodera, Y.,
Nakazawa, S., Ariyoshi, Y., Takahashi, T., et al. Two distinct portions of LTG19/
ENL at 19p13 are involved in t(11;19) leukemia. Oncogene, 8: 2617–2625, 1993.
Taki, T., Hayashi, Y., Taniwaki, M., Seto, M., Ueda, R., Hanada, R., Suzukawa, K.,
Yokota, J., and Morishita, K. Fusion of the MLL gene with two different genes, AF-6
and AF-5 ␣, by a complex translocation involving chromosomes 5, 6, 8, and 11 in
infant leukemia. Oncogene, 13: 2121–2130, 1996.
Dobson, C. L., Warren, A. J., Pannell, R., Forster, A., and Rabbitts, T. H. Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ
gene. EMBO J., 19: 843– 851, 2000.
Uckun, F. M., Herman-Hatten, K., Crotty, M. L., Sensel, M. G., Sather, H. N.,
Tuel-Ahlgren, L., Sarquis, M. B., Bostrom, B., Nachman, J. B., Steinherz, P. G.,
Gaynon, P. S., and Heerema, N. Clinical significance of MLL-AF4 fusion transcript
expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood, 92: 810 – 821, 1998.
Schnittger, S., Wormann, B., Hiddemann, W., and Griesinger, F. Partial tandem
duplications of the MLL gene are detectable in peripheral blood and bone marrow of
nearly all healthy donors. Blood, 92: 1728 –1734, 1998.
2669
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.
t(11;14)(q23;q24) Generates an MLL-Human Gephyrin Fusion
Gene along with a de facto Truncated MLL in Acute
Monoblastic Leukemia
Naruo Kuwada, Fumihiko Kimura, Takuya Matsumura, et al.
Cancer Res 2001;61:2665-2669.
Updated version
Cited articles
Citing articles
E-mail alerts
Reprints and
Subscriptions
Permissions
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/6/2665
This article cites 51 articles, 24 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/6/2665.full.html#ref-list-1
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/61/6/2665.full.html#related-urls
Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Department at [email protected].
To request permission to re-use all or part of this article, contact the AACR Publications
Department at [email protected].
Downloaded from cancerres.aacrjournals.org on June 15, 2017. © 2001 American Association for Cancer
Research.